A systems biology approach to drug development clinical testing of biomarkers for the anti-ErbB3 antibody MM-121 /

Viečča ollesdeavstta
Series

Human tumor antigens as therapeutic targets of cancer

Viečča ollesdeavstta
Series

Pharmacotherapy of osteoporosis part 2 of 2 /

Viečča ollesdeavstta
Series

Glucocorticoids, inflammation and bone loss

Viečča ollesdeavstta
Series

Nanotechnology platforms for cancer, and beyond

Viečča ollesdeavstta
Series

Pharmacometrics in pain management

Viečča ollesdeavstta

Pharmacometrics in psychiatry

Viečča ollesdeavstta

Osteoporosis how long to treat? /

Viečča ollesdeavstta
Series

Combination and sequential therapy for the treatment of Osteoporosis

Viečča ollesdeavstta
Series

Pharmacometric approaches to optimize use of drugs and dialysis treatments in patients with chronic kidney disease

Viečča ollesdeavstta
Series

Pharmacometrics in tuberculosis

Viečča ollesdeavstta
Series

The challenge of developing drugs for neglected parasitic diseases

Viečča ollesdeavstta
Series

Promising medical therapies for Parkinson's disease

Viečča ollesdeavstta
Series

Mechanisms of L-DOPA-induced dyskinesia in Parkinson's disease

Viečča ollesdeavstta
Series

Management of MDR and XDR TB

Viečča ollesdeavstta
Series

Acid-peptic diseases of the stomach and duodenum including Helicobacter pylori and NSAIDs

Viečča ollesdeavstta
Series

Infection in the cystic fibrosis lung

Viečča ollesdeavstta
Series

Receptors and channels in pain

Viečča ollesdeavstta
Series

Tuberculosis new treatments in evolution /

Viečča ollesdeavstta
Series

Key drug discovery challenges in cardiovascular medicine

Viečča ollesdeavstta
Series (Genetics of cardiovascular disease)
Series (Small molecule drug discovery)